CAS No. |
107452-89-1 |
|---|---|
中文名称 |
2-(63-氨基-13,45,54,60-四(4-氨基丁基)-16-氨基甲酰基-4,36-双(3-胍基丙基)-27-(4-羟基苄基)-71-(1-羟基乙基)-7,39,77-三(羟甲基)-33-异丁基-48-甲基-30-(2-甲硫基乙基)-2,5,8,11,14,23,26,29,32,35,38,41,44,47,50,53,56,59,62,69,72,75,78,85-二十四氧代-18,19,65,66,81,82-六硫杂-3,6,9,12,15,22,25,28,31,34,37,40,43,46,49,52,55,58,61,70,73,76,79,84-二十四氮杂三环[40.37.4.221,68]五十八烷-24-基)乙酸 |
英文名称 |
2-(63-amino-13,45,54,60-tetrakis(4-aminobutyl)-16-carbamoyl-4,36-bis(3-guanidinopropyl)-27-(4-hydroxybenzyl)-71-(1-hydroxyethyl)-7,39,77-tris(hydroxymethyl)-33-isobutyl-48-methyl-30-(2-(methylthio)ethyl)-2,5,8,11,14,23,26,29,32,35,38,41,44,47,50,53,56,59,62,69,72,75,78,85-tetracosaoxo-18,19,65,66,81,82-hexathia-3,6,9,12,15,22,25,28,31,34,37,40,43,46,49,52,55,58,61,70,73,76,79,84-tetracosaazatricyclo[40.37.4.221,68]pentaoctacontan-24-yl)acetic acid |
别名 |
OMEGA-CONOTOXIN MVIIA;OMEGA-CGTX MVII A;ZICONOTIDE ACETATE;snx111;H-CYS-LYS-GLY-LYS-GLY-ALA-LYS-CYS-SER-ARG-LEU-MET-TYR-ASP-CYS-CYS-THR-GLY-SER-CYS-ARG-SER-GLY-LYS-CYS-NH2;H-CYS-LYS-GLY-LYS-GLY-ALA-LYS-CYS-SER-ARG-LEU-MET-TYR-ASP-CYS-CYS-THR-GLY-SER-CYS-ARG-SER-GLY-LYS-CYS-NH2 (DISULFIDE BRIDGE: 1-16, 8-20, AND 15-25);CYS-LYS-GLY-LYS-GLY-ALA-LYS-CYS-SER-ARG-LEU-MET-TYR-ASP-CYS-CYS-THR-GLY-SER-CYS-ARG-SER-GLY-LYS-CYS-NH2;CKGKGAKCSRLMYDCCTGSCRSGKC-NH2 (DISULFIDE BRIDGE: 1-16,8-20, AND 15-25) |
标准英文名 |
2-(63-amino-13,45,54,60-tetrakis(4-aminobutyl)-16-carbamoyl-4,36-bis(3-guanidinopropyl)-27-(4-hydroxybenzyl)-71-(1-hydroxyethyl)-7,39,77-tris(hydroxymethyl)-33-isobutyl-48-methyl-30-(2-(methylthio)ethyl)-2,5,8,11,14,23,26,29,32,35,38,41,44,47,50,53,56,59,62,69,72,75,78,85-tetracosaoxo-18,19,65,66,81,82-hexathia-3,6,9,12,15,22,25,28,31,34,37,40,43,46,49,52,55,58,61,70,73,76,79,84-tetracosaazatricyclo[40.37.4.221,68]pentaoctacontan-24-yl)acetic acid |
分子式 |
C102H172N36O32S7 |
分子量 |
2639.19 |
精确分子量 |
2637.10 |
SMILES |
CSCCC1NC(=O)C(CC(C)C)NC(=O)C(CCCNC(=N)N)NC(=O)C(CO)NC(=O)C2CSSCC3NC(=O)C(CO)NC(=O)CNC(=O)C(C(C)O)NC(=O)C(CSSCC(N)C(=O)NC(CCCCN)C(=O)NCC(=O)NC(CCCCN)C(=O)NCC(=O)NC(C)C(=O)NC(CCCCN)C(=O)N2)NC(=O)C(CSSCC(C(N)=O)NC(=O)C(CCCCN)NC(=O)CNC(=O)C(CO)NC(=O)C(CCCNC(=N)N)NC3=O)NC(=O)C(CC(=O)O)NC(=O)C(CC2=CC=C(O)C=C2)NC1=O |
标准SMILES |
CC(C)CC1NC(=O)C(CCCNC(N)=N)NC(=O)C(CO)NC(=O)C2CSSCC3NC(=O)C(CO)NC(=O)CNC(=O)C(NC(=O)C(CSSCC(N)C(=O)NC(CCCCN)C(=O)NCC(=O)NC(CCCCN)C(=O)NCC(=O)NC(C)C(=O)NC(CCCCN)C(=O)N2)NC(=O)C(CSSCC(NC(=O)C(CCCCN)NC(=O)CNC(=O)C(CO)NC(=O)C(CCCNC(N)=N)NC3=O)C(N)=O)NC(=O)C(CC(O)=O)NC(=O)C(CC2=CC=C(O)C=C2)NC(=O)C(CCSC)NC1=O)C(C)O |
用途 |
Ziconotide is indicated for the management of severe chronic pain in patients who require intrathecal therapy and are intolerant of or refractory to other analgesic treatments (e.g., systemic analgesics or intrathecal morphine). It is used intrathecally to treat postherpetic neuralgia, phantom limb pain, HIV-associated neuropathic pain, refractory cancer pain, and postoperative pain. As a selective N-type voltage-sensitive calcium channel blocker (NCCB), ziconotide inhibits the release of excitatory neurotransmitters from primary nociceptive afferents in the superficial dorsal horn of the spinal cord, thereby blocking the transmission of nociceptive signals. It provides significant analgesic efficacy in patients with chronic pain due to cancer or AIDS who have failed other therapies. Additionally, ziconotide demonstrates neuroprotective effects in transient spinal cord ischemia by inhibiting N-type calcium channel activation during aortic surgery. |
InChIKey |
BPKIMPVREBSLAJ-UHFFFAOYSA-N |
|
|
评论 |
|---|